Lupin receives USFDA’s approval for generic Dovonex Scalp Solution

28 Dec 2017 Evaluate

Lupin has received final approval for its Calcipotriene Topical Solution, 0.005% (Scalp Solution) from the United States Food and Drug Administration (USFDA) to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products.

Lupin's Calcipotriene Topical Solution, 0.005% (Scalp Solution) is the AT rated generic equivalent of Leo Pharmaceutical Products' Dovonex Scalp Solution, 0.005%. It is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp.

Calcipotriene Topical Solution, 0.005% (Scalp Solution) had annual sales of approximately $5.9 million in the US (IMS MAT October 2017).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2138.65 -12.40 (-0.58%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×